Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurogenetics
Published in: neurogenetics 3-4/2013

01-11-2013 | Original Article

Neuroligin modulates the locomotory dopaminergic and serotonergic neuronal pathways of C. elegans

Authors: Patricia G. Izquierdo, Fernando Calahorro, Manuel Ruiz-Rubio

Published in: Neurogenetics | Issue 3-4/2013

Login to get access

Abstract

Neuroligins are neuronal and neuromuscular transmembrane proteins that have been implicated in autism spectrum disorder and other cognitive diseases. The nlg-1 gene from Caenorhabditis elegans is orthologous to human neuroligin genes. In the nematode, the locomotory rate is mediated by dopaminergic and serotonergic pathways, which result in two different behavioral responses known as basal slowing response (BSR) and enhanced slowing response (ESR), respectively. We report that nlg-1-deficient mutants are defective in both the BSR and ESR behaviors. In addition, we demonstrate that methylphenidate (a dopamine reuptake inhibitor) and fluoxetine (a serotonin reuptake inhibitor), two drugs widely used for the treatment of behavioral disorders in humans, are able to restore the BSR and ESR wild type phenotypes, respectively, in nlg-1 defective mutant nematodes. The abnormal locomotory behavior patterns were rescued in nlg-1-deficient mutant by expressing a cDNA from the human NLGN1 gene under the C. elegans nlg-1 promoter. However, human NLGN1 (R453C) and NLGN1 (D432X) mutant alleles did not rescue any of the two mutant phenotypes. The results indicate that neuroligin is involved in modulating the action of dopamine and serotonin in the nematode and suggest that the functional mechanism underpinning both methylphenidate and fluoxetine in C. elegans might be comparable to that in humans. The neuroligin-deficient mutants may undergo inefficient synaptic transmissions which could affect different traits in the nervous system. In particular, neuroligin might be required for normal neurotransmitters release. The understanding of the mechanisms by which methylphenidate and fluoxetine are able to restore the behavior of these mutants could help to explain the etiology of some human neurological diseases.
Appendix
Available only for authorised users
Literature
1.
Garber K (2007) Neuroscience. Autism's cause may reside in abnormalities at the synapse. Science 317(5835):190–191PubMedCrossRef
2.
Zoghbi HY (2003) Postnatal neurodevelopmental disorders: meeting at the synapse? Science 302(5646):826–830PubMedCrossRef
3.
Dean C, Dresbach T (2006) Neuroligins and neurexins: linking cell adhesion, synapse formation and cognitive function. Trends Neurosci 29(1):21–29PubMedCrossRef
4.
Etherton MR, Tabuchi K, Sharma M, Ko J, Sudhof TC (2011) An autism-associated point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA receptor-mediated synaptic transmission in hippocampus. EMBO J 30(14):2908–2919PubMedCrossRef
5.
Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, Soderstrom H, Giros B, Leboyer M, Gillberg C, Bourgeron T (2003) Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34(1):27–29PubMedCrossRef
6.
Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Ropers HH, Hamel BC, Andres C, Barthelemy C, Moraine C, Briault S (2004) X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 74(3):552–557PubMedCrossRef
7.
Lawson-Yuen A, Saldivar JS, Sommer S, Picker J (2008) Familial deletion within NLGN4 associated with autism and Tourette syndrome. Eur J Hum Genet 16(5):614–618PubMedCrossRef
8.
Talebizadeh Z, Bittel DC, Veatch OJ, Butler MG, Takahashi TN, Miles JH (2004) Do known mutations in neuroligin genes (NLGN3 and NLGN4) cause autism? J Autism Dev Disord 34(6):735–736PubMedCrossRef
9.
Wu S, Jia M, Ruan Y, Liu J, Guo Y, Shuang M, Gong X, Zhang Y, Yang X, Zhang D (2005) Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry 58(1):74–77PubMedCrossRef
10.
Hunter JW, Mullen GP, McManus JR, Heatherly JM, Duke A, Rand JB (2010) Neuroligin-deficient mutants of C. elegans have sensory processing deficits and are hypersensitive to oxidative stress and mercury toxicity. Dis Model Mech 3(5–6):366–376PubMedCrossRef
11.
Feinberg EH, Vanhoven MK, Bendesky A, Wang G, Fetter RD, Shen K, Bargmann CI (2008) GFP reconstitution across synaptic partners (GRASP) defines cell contacts and synapses in living nervous systems. Neuron 57(3):353–363PubMedCrossRef
12.
Hu Z, Hom S, Kudze T, Tong XJ, Choi S, Aramuni G, Zhang W, Kaplan JM (2012) Neurexin and neuroligin mediate retrograde synaptic inhibition in C. elegans. Science 337(6097):980–984PubMedCrossRef
13.
Calahorro F, Alejandre E, Ruiz-Rubio M (2009) Osmotic avoidance in Caenorhabditis elegans: synaptic function of two genes, orthologues of human NRXN1 and NLGN1, as candidates for autism. J Vis Exp 11(34):1616
14.
Calahorro F, Ruiz-Rubio M (2012) Functional phenotypic rescue of Caenorhabditis elegans neuroligin-deficient mutants by the human and rat NLGN1 genes. PLoS ONE 7(6):e39277PubMedCrossRef
15.
Gainetdinov RR, Caron MG (2003) Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 43:261–284PubMedCrossRef
16.
Iversen L (2006) Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 147(Suppl 1):S82–S88PubMed
17.
Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE (2003) Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 34(2):77–80PubMedCrossRef
18.
Byerley WF, Reimherr FW, Wood DR, Grosser BI (1988) Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 8(2):112–115PubMedCrossRef
19.
Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J (2008) Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther 14(2):153–164PubMedCrossRef
20.
Sawin ER, Ranganathan R, Horvitz HR (2000) C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26(3):619–631PubMedCrossRef
21.
Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77(1):71–94PubMed
22.
Granato M, Schnabel H, Schnabel R (1994) pha-1, a selectable marker for gene transfer in C. elegans. Nucleic Acids Res 22(9):1762–1763PubMedCrossRef
23.
McDonald PW, Hardie SL, Jessen TN, Carvelli L, Matthies DS, Blakely RD (2007) Vigorous motor activity in Caenorhabditis elegans requires efficient clearance of dopamine mediated by synaptic localization of the dopamine transporter DAT-1. J Neurosci 27(51):14216–14227PubMedCrossRef
24.
Carvelli L, McDonald PW, Blakely RD, Defelice LJ (2004) Dopamine transporters depolarize neurons by a channel mechanism. Proc Natl Acad Sci U S A 101(45):16046–16051PubMedCrossRef
25.
Jayanthi LD, Apparsundaram S, Malone MD, Ward E, Miller DM, Eppler M, Blakely RD (1998) The Caenorhabditis elegans gene T23G5.5 encodes an antidepressant- and cocaine-sensitive dopamine transporter. Mol Pharmacol 54(4):601–609PubMed
26.
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155(10):1325–1331PubMed
27.
Calahorro F, Ruiz-Rubio M (2011) Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder. Invert Neurosci 11:73–83PubMedCrossRef
28.
Challman TD, Lipsky JJ (2000) Methylphenidate: its pharmacology and uses. Mayo Clin Proc 75(7):711–721PubMed
29.
Vaswani M, Linda FK, Ramesh S (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuro-Psychopharmacol Biol Psychiatry 27(1):85–102CrossRef
30.
Calahorro F, Ruiz-Rubio M (2013) Human alpha- and beta-NRXN1 isoforms rescue behavioral impairments of Caenorhabditis elegans neurexin-deficient mutants. Genes Brain Behav 12(4):453–464PubMedCrossRef
Metadata
Title
Neuroligin modulates the locomotory dopaminergic and serotonergic neuronal pathways of C. elegans
Authors
Patricia G. Izquierdo
Fernando Calahorro
Manuel Ruiz-Rubio
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Neurogenetics / Issue 3-4/2013
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI
https://doi.org/10.1007/s10048-013-0377-6

Other articles of this Issue 3-4/2013

neurogenetics 3-4/2013 Go to the issue

Original Article

Autosomal recessive hereditary spastic paraplegia—clinical and genetic characteristics of a well-defined cohort

Original Article

Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington’s disease motor onset

Original Article

Chromosomal rearrangements in Tourette syndrome: implications for identification of candidate susceptibility genes and review of the literature

Editorial

Genetic modifiers in Huntington’s disease: fiction or fact?

Original Article

Homozygous truncating mutation of the KBP gene, encoding a KIF1B-binding protein, in a familial case of fetal polymicrogyria

Original Article

Diagnostic utility of whole exome sequencing in patients showing cerebellar and/or vermis atrophy in childhood